Medicus Pharma (NASDAQ:MDCX) Shares Down 5.2% – What’s Next?

by · The Markets Daily

Medicus Pharma Ltd (NASDAQ:MDCX – Get Free Report) dropped 5.2% during trading on Monday . The company traded as low as $0.32 and last traded at $0.32. Approximately 1,567,068 shares changed hands during trading, a decline of 31% from the average daily volume of 2,280,738 shares. The stock had previously closed at $0.3377.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on MDCX shares. Roth Mkm started coverage on Medicus Pharma in a research report on Tuesday, April 21st. They set a “buy” rating on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Medicus Pharma in a research report on Friday, April 10th. Finally, D. Boral Capital restated a “buy” rating and set a $9.00 price target on shares of Medicus Pharma in a research report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $9.00.

View Our Latest Analysis on Medicus Pharma

Medicus Pharma Stock Performance

The firm has a market capitalization of $19.93 million, a P/E ratio of -0.13 and a beta of 0.14. The stock has a 50-day moving average of $0.33 and a 200 day moving average of $0.91.

Medicus Pharma (NASDAQ:MDCX – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.13). On average, equities analysts predict that Medicus Pharma Ltd will post -0.51 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Yorkville Advisors Global LP bought a new position in Medicus Pharma in the 3rd quarter valued at $532,000. May Hill Capital LLC boosted its position in Medicus Pharma by 100.0% in the 4th quarter. May Hill Capital LLC now owns 35,622 shares of the company’s stock valued at $55,000 after buying an additional 17,811 shares during the last quarter. Wilmington Savings Fund Society FSB boosted its position in Medicus Pharma by 100.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock valued at $78,000 after buying an additional 25,622 shares during the last quarter. Jane Street Group LLC bought a new position in Medicus Pharma in the 4th quarter valued at $92,000. Finally, Private Advisor Group LLC boosted its position in Medicus Pharma by 3.8% in the 3rd quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock valued at $351,000 after buying an additional 5,500 shares during the last quarter.

Medicus Pharma Company Profile

(Get Free Report)

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.

Further Reading